Martingale Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,196
| Closed | -$353K | – | 832 |
|
|
2025
Q1 | $353K | Sell |
3,196
-19,659
| -86% | -$2.17M | 0.01% | 656 |
|
|
2024
Q4 | $3.12M | Sell |
22,855
-3,456
| -13% | -$472K | 0.08% | 204 |
|
|
2024
Q3 | $3.03M | Sell |
26,311
-3,400
| -11% | -$392K | 0.07% | 222 |
|
|
2024
Q2 | $4.09M | Sell |
29,711
-1,326
| -4% | -$183K | 0.09% | 177 |
|
|
2024
Q1 | $4.28M | Buy |
31,037
+4,530
| +17% | +$625K | 0.09% | 179 |
|
|
2023
Q4 | $3.49M | Buy |
26,507
+589
| +2% | +$77.6K | 0.07% | 185 |
|
|
2023
Q3 | $2.92M | Sell |
25,918
-1,954
| -7% | -$220K | 0.06% | 199 |
|
|
2023
Q2 | $2.63M | Buy |
27,872
+88
| +0.3% | +$8.3K | 0.05% | 218 |
|
|
2023
Q1 | $2.81M | Buy |
27,784
+6,061
| +28% | +$613K | 0.05% | 208 |
|
|
2022
Q4 | $2.59M | Buy |
+21,723
| New | +$2.59M | 0.05% | 212 |
|